Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

References

Page 1

	Year	Citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, JNCI Journal of the National Cancer Institute World Health OrganizationSolid TumorsCancer ManagementMetronomic ChemotherapyResponse Assessment	2000	15.7K
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, New England Journal of Medicine	2004	11.4K
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee, Science	2004	9.4K
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell, Enric Carcereny, Radj Gervais, The Lancet Oncology OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial Neoplasm	2012	5.5K
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Science	2007	4.4K
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Caicun Zhou, Yi‐Long Wu, Gongyan Chen, The Lancet Oncology MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment	2011	4K
<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, New England Journal of Medicine	2005	3.9K
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain William Pao, Vincent A. Miller, Katerina Politi, PLoS Medicine	2005	3.5K
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies Manuel Hidalgo, Lillian L. Siu, John Nemunaitis, Journal of Clinical Oncology	2001	997
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations Seiji Yano, Wei Wang, Qi Li, Cancer Research	2008	629

Page 1